Given the growing interest in tau-targeted therapeutics for Alzheimer’s disease (AD), there is a critical need for reliable and specific biomarkers of insoluble, aggregated tau to understand AD pathophysiology and to evaluate the effects of treatments1. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.